Dear Colleagues,

ESMO has launched an international collaborative project, the ESMO-CoCARE Registry, to quickly gather data and information from healthcare professionals about treatment approaches specifically focusing on the impact of SARS-CoV-2 on cancer patients who are suspected or confirmed to have the novel coronavirus disease (COVID-19).

The global spread of SARS-CoV-2 is posing unprecedented challenges at medical and societal levels and we all share a common cause in seeking to better understand the unique effects of COVID-19 on patients with cancer and cancer survivors.

By pooling real-world data, we will rapidly accumulate knowledge, which will allow us to disseminate information and guidance for this particularly vulnerable group of patients. We hope, ultimately, to propose approaches to mitigate the risks related to COVID-19 in cancer patients.

Joining the ESMO-CoCARE Registry will offer participating centres numerous benefits, including:

- The opportunity to collaborate in a joint endeavour with colleagues from around the world;
- Contributing to a better understanding of the effects of COVID-19 on cancer patients;
- Retaining full access to own patients’ data for further analysis.

The survey is comprised of several parts, including patient demographics, COVID-19 and cancer diagnosis and treatment, and the evolution of both diseases.

The ESMO-CoCARE Registry initiative is open to cancer centres and organisations from across Europe and around the world. It has a steering committee composed of nine experts, who specialise in a range of tumour types.

A partnership between this initiative and the COVID-19 and Cancer Consortium (CCC19) has also been established to broaden the reach of the registry and increase the rate at which information can be collected and disseminated about this major global emergency.

On behalf of the ESMO-CoCARE Registry Steering Committee, we strongly hope that as many collaborators as possible will consider joining this global effort to advance research for the benefit of our patients.

Sincerely,

Emanuela Romano, Institut Curie, Paris, France
Luis Castelo-Branco, Algarve University Centre, Portugal
Olivier Michielin, Lausanne University Hospital, Switzerland
Kevin J. Harrington, The Institute of Cancer Research, London, UK
Jean-Yves Douillard, Lugano, Switzerland (ESMO Chief Medical Officer)
Dirk Arnold, University Hamburg, Asklepios Tumorzentrum, AK Altona, Hamburg, Germany
Jennifer Whisenant Gray, Vanderbilt University, Nashville, TN, USA
Toni Choueiri, Dana-Farber Cancer Institute, Boston, MA, USA
Solange Peters, Lausanne University Hospital, Switzerland (ESMO President)